tradingkey.logo

Fulcrum Therapeutics Inc <FULC.OQ> expected to post a loss of 29 cents a share - Earnings Preview

ReutersJul 25, 2025 1:27 PM
  • Fulcrum Therapeutics Inc FULC.OQ FULC.O is expected to show a fall in quarterly revenue when it reports results on July 29 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Fulcrum Therapeutics Inc is for a loss of 29 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $9.00, about 13.1% above its last closing price of $7.82

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.30

-0.29

-0.28

Beat

4.8

Dec. 31 2025

-0.29

-0.32

-0.31

Beat

3.6

Sep. 30 2024

-0.41

-0.41

-0.35

Beat

13.7​

Jun. 30 2024

0.02

-0.01

0.87

Beat

7,060

​​Mar. 31 2024

-0.44

-0.44

-0.43

Beat

1.7

Dec. 31 2023

-0.42

-0.43

-0.40

Beat

6​

Sep. 30 2023

-0.43

-0.43

-0.39

Beat

10.3

Jun. 30 2023

-0.45

-0.44

-0.38

Beat

14.5

This summary was machine generated July 25 at 13:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI